-
1
-
-
30344479938
-
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
-
Smedby KE, Hjalgrim H, Askling J et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98: 51-60.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 51-60
-
-
Smedby, K.E.1
Hjalgrim, H.2
Askling, J.3
-
2
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
3
-
-
13244288836
-
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up
-
Czuczman MS, Weaver R, Alkuzweny B et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711-4716.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4711-4716
-
-
Czuczman, M.S.1
Weaver, R.2
Alkuzweny, B.3
-
4
-
-
28544435078
-
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
-
(2005)
Blood
, vol.106
, pp. 3725-3732
-
-
Hiddemann, W.1
Kneba, M.2
Dreyling, M.3
-
5
-
-
0035093233
-
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
-
Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-211.
-
(2001)
Rheumatology (Oxford)
, vol.40
, pp. 205-211
-
-
Edwards, J.C.1
Cambridge, G.2
-
7
-
-
0036785351
-
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
-
Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-888.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 883-888
-
-
Leandro, M.J.1
Edwards, J.C.2
Cambridge, G.3
-
8
-
-
2942537697
-
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
-
Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.
-
(2004)
N Engl J Med
, vol.350
, pp. 2572-2581
-
-
Edwards, J.C.1
Szczepanski, L.2
Szechinski, J.3
-
9
-
-
1842413105
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project
-
WHO
-
WHO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
-
(1997)
Blood
, vol.89
, pp. 3909-3918
-
-
-
10
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
-
NCI Sponsored International Working Group
-
Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
11
-
-
0642305396
-
Lymphoproliferation in autoimmunity and Sjogren's syndrome
-
Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep 2003; 5: 317-323.
-
(2003)
Curr Rheumatol Rep
, vol.5
, pp. 317-323
-
-
Voulgarelis, M.1
Moutsopoulos, H.M.2
-
12
-
-
0025813213
-
Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas
-
Dighiero G, Hart S, Lim A et al. Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood 1991; 78: 581-585.
-
(1991)
Blood
, vol.78
, pp. 581-585
-
-
Dighiero, G.1
Hart, S.2
Lim, A.3
-
13
-
-
0035560236
-
Extranodal lymphoma of MALT-type: Perspective at the beginning of the 21st century
-
Raderer M, Isaacson PG. Extranodal lymphoma of MALT-type: Perspective at the beginning of the 21st century. Expert Rev Anticancer Ther 2001; 1: 53-64.
-
(2001)
Expert Rev Anticancer Ther
, vol.1
, pp. 53-64
-
-
Raderer, M.1
Isaacson, P.G.2
-
14
-
-
33746547256
-
Long-term remission of Sjogren's syndrome-associated aggressive B-cell non-Hodgkin's lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
-
Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long-term remission of Sjogren's syndrome-associated aggressive B-cell non-Hodgkin's lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006; 65(8): 1033-37.
-
(2006)
Ann Rheum Dis
, vol.65
, Issue.8
, pp. 1033-1037
-
-
Voulgarelis, M.1
Giannouli, S.2
Tzioufas, A.G.3
Moutsopoulos, H.M.4
-
15
-
-
0037732689
-
The role of B cells in rheumatoid arthritis: Mechanisms and therapeutic targets
-
Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003; 15: 246-252.
-
(2003)
Curr Opin Rheumatol
, vol.15
, pp. 246-252
-
-
Dorner, T.1
Burmester, G.R.2
-
16
-
-
0033033201
-
Do self-perpetuating B lymphocytes drive human autoimmune disease?
-
Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 188-196.
-
(1999)
Immunology
, vol.97
, pp. 188-196
-
-
Edwards, J.C.1
Cambridge, G.2
Abrahams, V.M.3
-
17
-
-
0035888030
-
T cell activation in rheumatoid synovium is B cell dependent
-
Takemura S, Klimiuk PA, Braun A et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167: 4710-4718.
-
(2001)
J Immunol
, vol.167
, pp. 4710-4718
-
-
Takemura, S.1
Klimiuk, P.A.2
Braun, A.3
-
18
-
-
27744600435
-
Panel discussion on B cells and rituximab: Mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma
-
Panayi GS, Hainsworth JD, Looney RJ, Keystone EC. Panel discussion on B cells and rituximab: Mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma. Rheumatology (Oxford) 2005; 44 (Suppl 2): Ii18-ii20.
-
(2005)
Rheumatology (Oxford)
, vol.44
, Issue.SUPPL. 2
-
-
Panayi, G.S.1
Hainsworth, J.D.2
Looney, R.J.3
Keystone, E.C.4
-
19
-
-
29944439246
-
High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases
-
Cervetti G, Mechelli S, Riccioni R et al. High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol 2005; 23: 877-880.
-
(2005)
Clin Exp Rheumatol
, vol.23
, pp. 877-880
-
-
Cervetti, G.1
Mechelli, S.2
Riccioni, R.3
-
20
-
-
25444437442
-
Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study
-
Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren's syndrome: An open-label phase II study. Arthritis Rheum 2005; 52: 2740-2750.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2740-2750
-
-
Pijpe, J.1
van Imhoff, G.W.2
Spijkervet, F.K.3
-
21
-
-
7844225540
-
Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
-
Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
-
(1998)
Ann Oncol
, vol.9
, pp. 995-1001
-
-
Berinstein, N.L.1
Grillo-Lopez, A.J.2
White, C.A.3
-
22
-
-
0035259532
-
Re-treatment of relapsed indolent B-cell lymphoma with rituximab
-
Igarashi T, Ohtsu T, Fujii H et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73: 213-21.
-
(2001)
Int J Hematol
, vol.73
, pp. 213-221
-
-
Igarashi, T.1
Ohtsu, T.2
Fujii, H.3
-
23
-
-
27444441270
-
Update on rituximab
-
Eisenberg R. Update on rituximab. Ann Rheum Dis 2005; 64 (Suppl 4): iv55-iv57.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. 4
-
-
Eisenberg, R.1
-
24
-
-
0032533235
-
Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation
-
Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
-
(1998)
Blood
, vol.92
, pp. 3505-3514
-
-
Burt, R.K.1
Traynor, A.E.2
Pope, R.3
-
25
-
-
0036788483
-
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
-
Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 4022-4031.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4022-4031
-
-
Branson, K.1
Chopra, R.2
Kottaridis, P.D.3
|